Small molecule · Inhibitor of SHP2 (protein tyrosine phosphatase non-receptor type 11) (PTPN11) · developed by Revolution Medicines
Vociprotafib is an orally bioavailable inhibitor of SHP2, a protein tyrosine phosphatase encoded by PTPN11. By inhibiting SHP2 it blocks SHP2-mediated signaling through the RAS-RAF-MEK-ERK (MAPK) pathway, which is studied in non-small cell lung cancer and metastatic neoplasms.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05054725 | Phase 2 | Non-Small Cell Lung Cancer | Completed | RVMD |
| NCT04418661 | Phase 1/2 | Metastatic Neoplasm | Terminated | RVMD |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Metastatic NeoplasmNon-Small Cell Lung Cancer
Updated Nov 1, 2026. Something wrong or missing? Report it on the RVMD page.
See RVMD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
RVMD catalysts and pipeline →